Biosimilar medical products: What a physician needs to know
The Internet Journal of Family Practice · 2010
DOI: 10.5580/194a ↗At a glance
Journal article in The Internet Journal of Family Practice, 2010. Cited 1 times so far (Crossref).
Abstract (original language)
The first generation of approved biopharmaceuticals was developed a few decades ago. Drugs such as insulin, growth hormone, erythroprotein and cytokines were manufactured using recombinant DNA (rDNA) technology or hybridoma methods. They have improved the lives of countless patients of diabetes, short stature, anaemia, cancer, multiple sclerosis and hepatitis. Patents for many of these firstgeneration biotechnology products have, or are soon going to, expire. In many parts of world , strict patent laws are not in force. This has led to the development of various ‘copies” of these molecules by drug manufacturers. These products are known as biosimilars.
Cite
APA
(2010). Biosimilar medical products: What a physician needs to know. The Internet Journal of Family Practice. https://doi.org/10.5580/194a
Vancouver
Biosimilar medical products: What a physician needs to know. The Internet Journal of Family Practice. 2010. doi:10.5580/194a
BibTeX
@article{euvimed2010,
title = {Biosimilar medical products: What a physician needs to know},
journal = {The Internet Journal of Family Practice},
year = {2010},
doi = {10.5580/194a}
}
EUVIMED